Financial Architects Inc raised its stake in Stryker Co. (NYSE:SYK) by 386.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 1,235 shares of the medical technology company’s stock after purchasing an additional 981 shares during the period. Financial Architects Inc’s holdings in Stryker were worth $206,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Stryker by 1.6% in the 4th quarter. State Street Corp now owns 13,676,289 shares of the medical technology company’s stock valued at $2,879,007,000 after buying an additional 213,858 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Stryker by 0.4% in the 1st quarter. Bank of New York Mellon Corp now owns 7,006,593 shares of the medical technology company’s stock valued at $1,166,528,000 after buying an additional 28,171 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Stryker by 4.2% in the 4th quarter. Geode Capital Management LLC now owns 4,579,828 shares of the medical technology company’s stock valued at $959,331,000 after buying an additional 185,637 shares during the period. Norges Bank acquired a new position in shares of Stryker in the 4th quarter valued at about $604,447,000. Finally, Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Stryker by 50.9% in the 1st quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 2,012,015 shares of the medical technology company’s stock valued at $334,980,000 after buying an additional 678,536 shares during the period. 73.06% of the stock is owned by institutional investors.

Shares of NYSE SYK traded up $0.89 during midday trading on Friday, reaching $180.27. The company’s stock had a trading volume of 2,898,783 shares, compared to its average volume of 2,179,187. The company has a current ratio of 2.58, a quick ratio of 1.77 and a debt-to-equity ratio of 0.72. The company has a 50 day moving average price of $176.21 and a 200 day moving average price of $196.08. Stryker Co. has a one year low of $124.54 and a one year high of $226.30. The company has a market cap of $67.90 billion, a price-to-earnings ratio of 31.68, a price-to-earnings-growth ratio of 3.37 and a beta of 0.85.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, April 30th. The medical technology company reported $1.84 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.69 by $0.15. Stryker had a net margin of 14.47% and a return on equity of 24.90%. The business had revenue of $3.59 billion for the quarter, compared to analyst estimates of $3.45 billion. During the same quarter in the previous year, the business earned $1.88 earnings per share. The firm’s revenue was up 2.0% compared to the same quarter last year. Research analysts anticipate that Stryker Co. will post 6.2 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be given a $0.575 dividend. This represents a $2.30 annualized dividend and a yield of 1.28%. The ex-dividend date is Monday, June 29th. Stryker’s dividend payout ratio is 27.85%.

In other news, Director Srikant M. Datar sold 200 shares of the stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $186.01, for a total value of $37,202.00. Following the completion of the transaction, the director now owns 17,686 shares in the company, valued at approximately $3,289,772.86. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Katherine Ann Owen sold 3,121 shares of the company’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $190.81, for a total transaction of $595,518.01. Following the completion of the sale, the vice president now directly owns 4,481 shares in the company, valued at approximately $855,019.61. The disclosure for this sale can be found here. Insiders sold 12,670 shares of company stock valued at $2,380,526 over the last three months. Insiders own 6.80% of the company’s stock.

Several research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of Stryker from $210.00 to $215.00 and gave the company an “overweight” rating in a report on Friday, May 1st. Stifel Nicolaus boosted their target price on shares of Stryker from $145.00 to $205.00 and gave the company a “buy” rating in a research note on Friday, May 1st. Cfra reduced their target price on shares of Stryker from $234.00 to $231.00 and set a “strong-buy” rating for the company in a research note on Friday, May 1st. Goldman Sachs Group lowered shares of Stryker from a “buy” rating to a “sell” rating and reduced their target price for the company from $248.00 to $150.00 in a research note on Wednesday, April 1st. Finally, Cowen reduced their target price on shares of Stryker from $240.00 to $220.00 and set an “outperform” rating for the company in a research note on Wednesday, April 22nd. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $214.23.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Featured Story: Return on Equity (ROE)

Want to see what other hedge funds are holding SYK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stryker Co. (NYSE:SYK).

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.